TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03591458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Participants will receive a supply of Amitriptyline capsules for titration, intervention, and taper periods.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a supply of Placebo capsules, matching those of Amitriptyline, for the titration, intervention, and taper periods
Study: NCT04601909

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00371839

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Audiological Evaluation
Description: Tests of hearing, cognition, and speech perception

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Audiological Evaluation
Description: Tests of hearing, cognition, and speech perception

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Audiological Evaluation
Description: Tests of hearing, cognition, and speech perception
Study: NCT01899755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2800528, solution for injection
Description: Drug will be administered at 3 different dose levels by subcutaneous injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% w/v Sodium Chloride), solution for injection
Description: Subcutaneous injection of. 0.8 mL solution will be administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab, solution for injection
Description: Subcutaneous injection of 0.8 mL solution will be administered (40mg)
Study: NCT02724644

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COLLAGENASE CLOSTRIDIUM HISTOLYTICUM
Description: Injectable intervention

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study: NCT03911037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: G-CSF
Description: G-CSF will be administered as prefilled syringes at a dosage of 5 μg/Kg subcutaneously every 12 hr for five consecutive days. Four such cycles will be administered at three monthly intervals.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ( prefilled syringe) filled with normal saline subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
Study: NCT02488408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib
Study: NCT00330096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hesperidin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00780039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin
Description: Subjects will receive Caleyx 30 mg/m2 intravenously on Day 1 of each 4-week cycle, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
Study: NCT02488408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Study: NCT03183609

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluten Flour in Protein Shake
Description: 15 Grams Gluten Flour BID

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rice Flour in Protein Shake
Description: 15 Grams Rice Flour BID
Study: NCT03957226

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: e-OPRA (electronic-Osseoanchored Prosthese for the Rehabilitation of Amputees)
Description: The e-OPRA is an implant system that provides an alternative to traditional socket prostheses by establishing a direct, load-bearing link between the patient's skeleton and a prosthesis for transhumeral amputees. The anchorage element of the system is implanted directly into the bone while the electrodes that provide control signals for the prosthesis are implanted into muscle grafts on the transhumeral amputation.
Study: NCT02651272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: macitentan
Description: 10mg macitentan tablets
Study: NCT02412085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Subcutaneous golimumab. Induction regimen: 200 mg (week 0), 100 mg (week 2)~Maintenance regimen:~* body weight \< 80kg: 50 mg every 4 weeks~* body weight ≥ 80 kg: 100 mg every 4 weeks
Study: NCT04538950

Intervention type: DRUG
Group type: OTHER
Intervention: radioactive drug (tracer)
Description: A radioactive drug (tracer) is used in the PET scan.
Study: NCT01625715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen
Description: titrated dose: 1 mg once a day, then 1 mg twice a day then 2 mg twice a day
Study: NCT03057730

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix
Description: ADM is a human-derived allograft material, treated to remove all cellular components so that only the connective tissue matrix remains.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acellular Dermal Matrix
Description: ADM is a human-derived allograft material, treated to remove all cellular components so that only the connective tissue matrix remains.
Study: NCT02615249

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Metal Allergen Epicutaneous Patch
Description: 48 hour application of metal allergen patch to diagnose contact dermatitis
Study: NCT01258439

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: raltegravir plus truvada
Description: raltegravir 400 mg tablet with truvada 300/200 mg tablet for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir, ritonavir, tenofovir/emtricitabine (Truvada)
Description: Darunavir two 400mg tablets with one ritonavir 100mg capsule once daily plus Tenofovir/emtricitabine (Truvada) one 300mg/200mg tablet once daily with food for 24 weeks
Study: NCT00780039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Subjects will receive carboplatin dosed to target AUC of 5 mg/mL.min, intravenously, on Day 1 of each 4-week cycle, after the Caelyx infusion, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
Study: NCT02961725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCMSC
Description: UCMSC: umbilical cord mesenchymal stem cells 3-5\*10\^7/5 ml
Study: NCT03294304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given at a fixed dose of 360 mg IV over 30 minutes on Day 8 every 21 days for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be given at 70 mg/m2 IV over 30 minutes on Day 1 every 21 days, and based on treating physician's discretion, split-dose cisplatin can be given at 35 mg/m2 IV Day 1 and Day 8 every 21 days for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1, 8, and every 21 days for 4 cycles.
Study: NCT02196103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double balloon cervical catheter
Study: NCT04257617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZL-1201
Description: Part 1 \& 2: Escalating dose of ZL-1201, Part 3: three dose levels determined from Part 1 and Part 2.
Study: NCT01258855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given IV
Study: NCT01576471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trichuris suis ova (TSO)
Description: TSO 7500: 7500 embryonated, viable TSO every 2 weeks X 10 weeks (up to 6 total doses)
Study: NCT01258855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01576471

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: dose every 2 weeks X 10 weeks (up to 6 total doses)
Study: NCT04614792

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: Non-invasive brain stimulation or neuromodulation.
Study: NCT01258855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ziv-Aflibercept
Description: Given IV
Study: NCT00382070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg taken orally once daily for 5 years

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet taken orally once daily for 5 years
Study: NCT01552889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care
Description: No direct treatment will be offered. We will make treatment recommendations to the patient, PCP and cardiologist. Referral to mental health specialist is also possible, depending on need. The nurse case manager will monitor treatment progress and patient status for duration of the intervention period.
Study: NCT01333189

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight-bearing biofeedback exercise
Description: Patients in the experimental group completed the same standard of care rehabilitation program as the control group. Thus, the experimental intervention was in addition to the standard intervention.~Upon discharge to home, patients in the RELOAD group began the weight bearing (WB) biofeedback phase of the study. Patients participated in two 30-minute training sessions/week with a physical therapist for a total of 6 weeks, focusing on promoting WB symmetry using a progressive series of activities adapted to video games.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care exercise
Description: Standard inpatient rehabilitation began on post-operative day 1 and lasted for an average of 3.2 days. After hospital discharge, two weeks of home rehabilitation (6 visits) were provided by physical therapists. Patients progressed to outpatient rehabilitation, consisting of 4 weeks of treatment. As such, 6 weeks of rehabilitation following hospital discharge was implemented for both groups.
Study: NCT00488527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Description: Patients will begin with a fixed, subcutaneous dose of insulin glargine, (10 U), in its commercial presentation, which will be adjusted week by week, according to the values of the glycemia when fasting (FBG), adding 2, 4, 6 or 8 units of insulin glargine over the following twelve weeks, during which the therapeutic objective should be attained, namely the glucose goal during fasting of 100 mg/dl (\<6.0 mmol/L), and the active treatment is to be continued for three more months.
Study: NCT01765621

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DDI+ System and Pharmacogenetic Data
Study: NCT02360501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/㎡,d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/㎡,d1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 2000mg/㎡,d1-14
Study: NCT00879359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin, paclitaxel, and bevacizumab
Description: All patients enrolled will receive carboplatin AUC 5 plus paclitaxel 175 mg/m2 (135 mg/m2 if prior radiation to greater than 25% of bone marrow) plus bevacizumab 15 mg/kg every 3 weeks.
Study: NCT02729961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceritinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01309880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test lens
Description: Investigational silicone hydrogel contact lens worn on a daily wear basis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air Optix Aqua
Description: Air Optix Aqua contact lens worn on a daily wear basis
Study: NCT03149419

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Study: NCT03763383

Intervention type: PROCEDURE
Intervention: Lateral Arm Flap
Description: Its a kind of flap that is harvested from the lateral aspect of the arm to cover defects in different parts of the body

Intervention type: PROCEDURE
Intervention: Lateral Arm Flap
Description: Its a kind of flap that is harvested from the lateral aspect of the arm to cover defects in different parts of the body
Study: NCT00855582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: tablet once daily by mouth for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: tablet once daily by mouth for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching 2.5 or 5 mg placebo tablet once daily by mouth for 12 weeks.
Study: NCT03083379

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Volumetric Incentive Spirometry
Description: A study investigator will provide instruction on Incentive Spirometry procedure performance before supervised therapy and monitoring begins.~* Five minutes of eupneic ventilation EIT monitoring will occur before I.S. therapy commences.~* Study participants will be asked to take 10 deep breaths through the incentive spirometer's mouthpiece, followed by a 60 second pause.~* The 10-breath cycle will be repeated three times with respiratory therapist coaching.~* Five minutes of eupneic ventilation EIT monitoring will occur following the last I.S. lung expansion therapy breath cycle.~* Incentive Spirometry therapy and monitoring session will last about 15 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EzPAP® POSITIVE AIRWAY PRESSURE
Description: * A study investigator will provide instruction on EzPAP® procedure performance before supervised therapy and monitoring begins. A second study investigator will perform EIT device set-up and monitoring only.~* Five minutes of eupneic ventilation EIT monitoring will occur before EzPAP® therapy commences.~* Study participants will be asked to breathe normally through the EzPAP® device's mouthpiece for 10 breaths, followed by a 60 second pause.~* The 10-breath cycle will be repeated three times with respiratory therapist coaching.~* Five minutes of eupneic ventilation EIT monitoring will occur following the last EzPAP® lung expansion therapy breath cycle.~* EzPAP® therapy and monitoring sessions will last about 15 minutes
Study: NCT01850940

Intervention type: DRUG
Intervention: Tolvaptan
Description: Tolvaptan (OPC-41061) is a benzazepine derivative synthesized by Otsuka Pharmaceutical Company, Ltd. Tolvaptan was approved for the treatment of specific forms of hyponatremia by the United States (US) Food and Drug Administration (FDA) in May 2009, the European Medicines Agency on Aug 2009, Japan (Oct 2010), China (Sep 2011) and Korea (Sep 2011). Tolvaptan was approved for the adjunct treatment of volume overload in heart failure by the Japanese Ministry of Health, Labour, and Welfare (MHLW) in Oct 2010. It is also being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and for the treatment of hepatic edema.
Study: NCT02729961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT04970680

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: glossopharyngeal nerve block
Description: glossopharyngeal nerve block either blindly or using the ultrasonic technique

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: glossopharyngeal nerve block
Description: glossopharyngeal nerve block either blindly or using the ultrasonic technique
Study: NCT00327444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Description: 4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
Study: NCT01850940

Intervention type: OTHER
Intervention: conventional thearpy
Description: conventional therapy with salt limitation ,et al
Study: NCT00327444

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Description: 4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the OL period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Description: 4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the OL period.
Study: NCT03490786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT-001
Description: PK, PD Study to Determine Safety of Escalating Doses of GT-001
Study: NCT00066781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study: NCT01191996

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MIS416
Description: MIS416 intravenously every week
Study: NCT03140631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Protamine Sulfate
Description: Protamine sulfate is a highly basic protein that forms stable compounds with acidic heparin to rapidly neutralize the anticoagulation effects.
Study: NCT00959153

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LithoSpace Extracorporeal Shockwave Lithotripter
Description: Shockwave therapy to break up kidney stones
Study: NCT02906540

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transpubic symphysis reset therapy group
Description: The patients in the treatment group will undergo daily transpubic symphysis reset therapy for 7 consecutive days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy group
Description: The patients in the control group will undergo physiotherapy and a sham treatment.
Study: NCT03315247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based CBT
Description: The Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks at regular time intervals and recording consumption using food records, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and reducing vulnerability to overeating by solving problems and challenging negative thoughts. Participants are expected to complete CBT homework between sessions, such as completing food records, engaging in pleasurable and self-care activities, and completing a variety of worksheets.
Study: NCT00834964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine 25 mg Tablets
Description: 1 x 25 mg, single-dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effexor® 25 mg Tablets
Description: 1 x 25 mg, single-dose fasting
Study: NCT02651948

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperineal, MRI-guided, prostate biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transrectal prostate biopsy (TRB):
Study: NCT03807037

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tocotrienols
Description: Mixed tocotrienols (derived from palm oil) to be orally administered at 200mg (1 capsule) twice daily, to achieve dosage of 400mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo to be administered orally at 1 capsule, twice daily
Study: NCT02561611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: The content of both intervention components will be covered during a weekly scheduled group meeting (or face-to-face meetings, as needed). The step-counting component of the WMPD intervention will be modeled off the success of The First Step Program (FSP).
Study: NCT02091713

Intervention type: OTHER
Intervention: Functional movement screen
Description: The subjects will undergo movement and balance screens, measures of power, demographic data and biopsychosocial measures. Injury data will be collected through physician exam, self-report, profile data, and healthcare utilization data. Injury data will be collected at baseline and for six iterations, every 60 days, over the course of one year following baseline. Based on the data collected, clinical prediction rules will be used to develop computerized algorithm to predict injury risk in these populations.
Study: NCT02175095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Regorafenib will be administered 160 mg/day given orally on day 1 to days 21 following 7 days break, which consists of 4 weeks as 1 cycle. Treatment will be repeated every 4 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]FLT-PET
Description: \[18F\]FLT-PET scans before and on 21st day from the administration of regorafenib.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]FDG-PET
Description: \[18F\]FDG-PET will be performed before treatment and at 21 days after treatment.
Study: NCT03040362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-lasmiditan
Description: \[14C\]-lasmiditan as a 200 mg (approximately 100 µCi) oral solution
Study: NCT00507572

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Medical records are reviewed